Projects

MUVON co-founder and CEO interviewed by “Die Welt” (online version Gesunder Körper)

Dr. Deana Mohr explained, in this interview, her and her team’s commitment to the stress incontinence topic and what they plan to achieve in the short and long term at MUVON.

“We want to break the taboo and talk about the problems associated with incontinence or bladder weakness.

In the long term, we want to establish ourselves as the developer of the first cost-effective regenerative therapy for non-life-threatening diseases. We want to help people with incontinence lead a normal life again and improve their quality of life in the long term.”

Learn more reading the full article.

Read more

Recommended News

Annual Event 10 Years Wyss Zurich

Wyss Zurich celebrated its 10th anniversary at the Annual Event on November 3rd 2025. Over 300 guests gathered at the Kongresshaus Zurich to celebrate 10 years of impact by the Wyss Zurich Translational Center.

MYNERVA wins the Diamond Prize of MassChallange 2025

MassChallenge Switzerland, part of MassChallenge’s global network for innovators and zero-equity startup accelerators, yesterday hosted its 10th Anniversary Awards Ceremony in Lausanne, Switzerland.

Turning Ideas into Impact — Tethys Robotics raises Eur 3.5M

Wyss Zurich congratulates Tethys Robotics on raising €3.5 million to expand its autonomous underwater robot, Tethys ONE — advancing safety-critical missions from offshore energy to search and rescue.
Scion Day

Bridging Innovation and Implementation: Remote Robotic Surgery and the Future of Secure Connectivity

Wyss Zurich celebrates its alumni Nanoflex Robotics for contributing to the discussion on the future of remote robotic surgery. At SCION Day 2025, experts explored how 5G and SCION networks can enable safe, real-time surgical interventions.
MYNERVA News

Smart socks that alleviate pain

Diabetes leads to nerve damage in half of all people affected, starting in the feet. The smart sock from ETH spin-off MYNERVA helps sufferers feel the ground again when walking and alleviates their chronic pain.

Interview: Dr. Ana Montalban-Arques on Adularia’s Strategic Transition to Molecular Cancer Treatments

A lot changes in the first few years of a startup. This was also the case at Adularia, formerly Recolony: a discovery in the laboratory led to a new focus, which resulted in the repositioning of the entire company.

Sign up for our newsletter!

For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.